Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corneal Endothelial Cell Therapy for Corneal Endothelial Cell Dysfunction
NCT06726174Phase 1Active, not recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ECCEC in corneal endothelial cell dysfunction (FECD), sponsored by National Taiwan University Hospital. Primary endpoint: Corneal Endothelial Cell density at 24 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
ECCEC
03
Conditions
corneal endothelial cell dysfunction (FECD)
Beyond the preview
Go deeper on NCT06726174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726174.